{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:20:11Z","timestamp":1795281611093,"version":"4.10.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13555-025-01421-2","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:52:15Z","timestamp":1746456735000},"page":"1607-1631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Local Corticosteroids for Alopecia Areata: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Samantha","family":"Gregoire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Biba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primer. 2017;3:17011.","journal-title":"Nat Rev Dis Primer"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et\u00a0al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther. 2021;11:867\u201383.","journal-title":"Dermatol Ther"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, Fridman M, Vaghela S, Mostaghimi A. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther. 2023;13:285\u201398.","journal-title":"Dermatol Ther"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13555-023-00941-z","volume":"13","author":"N Mesinkovska","year":"2023","unstructured":"Mesinkovska N, Craiglow B, Ball SG, et\u00a0al. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol Ther. 2023;13:1503\u201315.","journal-title":"Dermatol Ther"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2147\/CCID.S445646","volume":"17","author":"A Bewley","year":"2024","unstructured":"Bewley A, Figueras-Nart I, Zhang J, et\u00a0al. Patient-reported burden of severe alopecia areata: first results from the multinational alopecia areata unmet need survey. Clin Cosmet Investig Dermatol. 2024;17:751\u201361.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1421_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/jdv.18926","volume":"37","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol JEADV. 2023;37:1490\u2013520.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jamadermatol.2023.3109","volume":"159","author":"H Lee","year":"2023","unstructured":"Lee H, Huang KP, Mostaghimi A, Choudhry NK. Treatment patterns for alopecia areata in the US. JAMA Dermatol. 2023;159:1253\u20137.","journal-title":"JAMA Dermatol"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2024","unstructured":"Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2024;192:190\u2013205.","journal-title":"Br J Dermatol"},{"key":"1421_CR9","first-page":"609","volume":"154","author":"A Rossi","year":"2019","unstructured":"Rossi A, Muscianese M, Piraccini BM, et\u00a0al. Italian Guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2019;154:609\u201323.","journal-title":"G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4103\/0378-6323.178903","volume":"82","author":"AB Mehta","year":"2016","unstructured":"Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371\u20138.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"15\u201331","key":"1421_CR11","first-page":"vii","volume":"42","author":"S Ramamoorthy","year":"2016","unstructured":"Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin N Am. 2016;42(15\u201331):vii.","journal-title":"Rheum Dis Clin N Am"},{"key":"1421_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/ar398","volume":"4","author":"J Saklatvala","year":"2002","unstructured":"Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res. 2002;4:146\u201350.","journal-title":"Arthritis Res"},{"key":"1421_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0039.2006.00599.x","volume":"68","author":"I Rogatsky","year":"2006","unstructured":"Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006;68:1\u201312.","journal-title":"Tissue Antigens"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.16808","volume":"179","author":"F Rajabi","year":"2018","unstructured":"Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179:1033\u201348.","journal-title":"Br J Dermatol"},{"key":"1421_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103061","volume":"21","author":"SJ Connell","year":"2022","unstructured":"Connell SJ, Jabbari A. The current state of knowledge of the immune ecosystem in alopecia areata. Autoimmun Rev. 2022;21: 103061.","journal-title":"Autoimmun Rev"},{"key":"1421_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000247111","volume":"188","author":"R Imai","year":"1994","unstructured":"Imai R, Takamori K, Ogawa H. Changes in populations of HLA-DR+CD3+ cells and CD57-CD16+ cells in alopecia areata after corticosteroid therapy. Dermatol Basel Switz. 1994;188:103\u20137.","journal-title":"Dermatol Basel Switz"},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jisp.2017.10.014","volume":"19","author":"R Paus","year":"2018","unstructured":"Paus R, Bulfone-Paus S, Bertolini M. Hair follicle immune privilege revisited: the key to alopecia areata management. J Investig Dermatol Symp Proc. 2018;19:S12\u20137.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1421_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejpb.2007.08.007","volume":"68","author":"S Wiedersberg","year":"2008","unstructured":"Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2008;68:453\u201366.","journal-title":"Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV"},{"key":"1421_CR19","first-page":"135","volume":"96","author":"ZD Draelos","year":"2015","unstructured":"Draelos ZD. Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study. Cutis. 2015;96:135\u201341.","journal-title":"Cutis"},{"key":"1421_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.sder.2008.12.002","volume":"28","author":"S Garg","year":"2009","unstructured":"Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg. 2009;28:15\u20138.","journal-title":"Semin Cutan Med Surg"},{"key":"1421_CR21","first-page":"757","volume":"61","author":"F Spano","year":"2015","unstructured":"Spano F, Donovan JC. Alopecia areata: part 2: treatment. Can Fam Physician Med Fam Can. 2015;61:757\u201361.","journal-title":"Can Fam Physician Med Fam Can"},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/JCAS.JCAS_96_18","volume":"11","author":"I Majid","year":"2018","unstructured":"Majid I, Jeelani S, Imran S. Fractional carbon dioxide laser in combination with topical corticosteroid application in resistant alopecia areata: a case series. J Cutan Aesthet Surg. 2018;11:217\u201321.","journal-title":"J Cutan Aesthet Surg"},{"key":"1421_CR23","first-page":"1","volume":"24","author":"L Jia","year":"2024","unstructured":"Jia L, Zhao C, Zhang H, Jiang H, Xiong J, Li Y. Combination therapy with CGF and microneedling-assisted compound betamethasone for resistant alopecia areata: a pilot study. J Cosmet Dermatol. 2024;24:1\u20137.","journal-title":"J Cosmet Dermatol"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/archderm.1986.01660210057018","volume":"122","author":"JM Garden","year":"1986","unstructured":"Garden JM, Freinkel RK. Systemic absorption of topical steroids. Metabolic effects as an index of mild hypercortisolism. Arch Dermatol. 1986;122:1007\u201310.","journal-title":"Arch Dermatol"},{"key":"1421_CR25","first-page":"643","volume":"16","author":"M Nakamura","year":"2017","unstructured":"Nakamura M, Abrouk M, Zhu H, Farahnik B, Koo J, Bhutani T. Update on the systemic risks of superpotent topical steroids. J Drugs Dermatol JDD. 2017;16:643\u20138.","journal-title":"J Drugs Dermatol JDD"},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","volume":"16","author":"EC Siegfried","year":"2016","unstructured":"Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.","journal-title":"BMC Pediatr"},{"key":"1421_CR27","first-page":"4802172","volume":"2018","author":"AA Milyani","year":"2018","unstructured":"Milyani AA, Al-Agha AE. Implication of topical steroids in the onset of osteoporosis. Case Rep Pediatr. 2018;2018:4802172.","journal-title":"Case Rep Pediatr"},{"key":"1421_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4274\/jcrpe.galenos.2020.2019.0220","volume":"12","author":"A G\u00fcven","year":"2020","unstructured":"G\u00fcven A. Different potent glucocorticoids, different routes of exposure but the same result: iatrogenic Cushing\u2019s syndrome and adrenal insufficiency. J Clin Res Pediatr Endocrinol. 2020;12:383\u201392.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"1421_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0733-8635(05)70017-6","volume":"16","author":"J Shapiro","year":"1998","unstructured":"Shapiro J, Price VH. Hair regrowth. Dermatol Clin. 1998;16:341\u201356.","journal-title":"Dermatol Clin"},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-7753.66920","volume":"2","author":"M Kumaresan","year":"2010","unstructured":"Kumaresan M. Intralesional steroids for alopecia areata. Int J Trichol. 2010;2:63\u20135.","journal-title":"Int J Trichol"},{"key":"1421_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2015.04.049","volume":"73","author":"TW Chu","year":"2015","unstructured":"Chu TW, AlJasser M, Alharbi A, Abahussein O, McElwee K, Shapiro J. Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: an intrasubject pilot study. J Am Acad Dermatol. 2015;73:338\u201340.","journal-title":"J Am Acad Dermatol"},{"key":"1421_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/CCID.S22767","volume":"4","author":"A Alsantali","year":"2011","unstructured":"Alsantali A. Alopecia areata: a new treatment plan. Clin Cosmet Investig Dermatol. 2011;4:107\u201315.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1421_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/0378-6323.110767","volume":"79","author":"S Ganjoo","year":"2013","unstructured":"Ganjoo S, Thappa DM. Dermoscopic evaluation of therapeutic response to an intralesional corticosteroid in the treatment of alopecia areata. Indian J Dermatol Venereol Leprol. 2013;79:408.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"1421_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14555","volume":"34","author":"MB Rajan","year":"2021","unstructured":"Rajan MB, Bhardwaj A, Singh S, et\u00a0al. Identification of novel step-up regimen of intralesional triamcinolone acetonide in scalp alopecia areata based on a double-blind randomized controlled trial. Dermatol Ther. 2021;34: e14555.","journal-title":"Dermatol Ther"},{"key":"1421_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000252466","volume":"141","author":"F Pascher","year":"1970","unstructured":"Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica. 1970;141:193\u2013202.","journal-title":"Dermatologica"},{"key":"1421_CR36","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/j.1468-3083.2006.01781.x","volume":"20","author":"A Tosti","year":"2006","unstructured":"Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol JEADV. 2006;20:1243\u20137.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"1421_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1067\/mjd.2003.423","volume":"49","author":"A Tosti","year":"2003","unstructured":"Tosti A, Piraccini BM, Pazzaglia M, Vincenzi C. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis\/universalis. J Am Acad Dermatol. 2003;49:96\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1421_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jamadermatol.2013.5764","volume":"150","author":"P Lenane","year":"2014","unstructured":"Lenane P, Macarthur C, Parkin PC, et\u00a0al. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. JAMA Dermatol. 2014;150:47\u201350.","journal-title":"JAMA Dermatol"},{"key":"1421_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1365-4362.2003.01862.x","volume":"42","author":"G Mancuso","year":"2003","unstructured":"Mancuso G, Balducci A, Casadio C, et\u00a0al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol. 2003;42:572\u20135.","journal-title":"Int J Dermatol"},{"key":"1421_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/archderm.136.10.1276","volume":"136","author":"S Charuwichitratana","year":"2000","unstructured":"Charuwichitratana S, Wattanakrai P, Tanrattanakorn S. Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol. 2000;136:1276\u20137.","journal-title":"Arch Dermatol"},{"key":"1421_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/09546634.2011.590788","volume":"23","author":"H Ucak","year":"2012","unstructured":"Ucak H, Kandi B, Cicek D, Halisdemir N, Dertl\u0131o\u011flu SB. The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J Dermatol Treat. 2012;23:410\u201320.","journal-title":"J Dermatol Treat"},{"key":"1421_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4103\/0974-7753.111223","volume":"4","author":"VR Sardesai","year":"2012","unstructured":"Sardesai VR, Prasad S, Agarwal TD. A study to evaluate the efficacy of various topical treatment modalities for alopecia areata. Int J Trichol. 2012;4:265\u201370.","journal-title":"Int J Trichol"},{"key":"1421_CR43","doi-asserted-by":"crossref","unstructured":"Tiwari AK, Ameta P, Garg P, Aara N. Comparative evaluation of topical betamethasone dipropionate lotion 0.05% versus its combination with intralesional triamcinolone acetonide injection in alopecia areata: a randomised controlled trial. J Clin Diagn Res [Internet]. 2023 [cited 2024 Aug 26]; https:\/\/www.jcdr.net\/\/article_fulltext.asp?issn=0973-709x&year=2023&volume=17&issue=7&page=WC01&issn=0973-709x&id=18247.","DOI":"10.7860\/JCDR\/2023\/62881.18247"},{"key":"1421_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2133.1973.tb06672.x","volume":"88","author":"E Abell","year":"1973","unstructured":"Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol. 1973;88:55\u20139.","journal-title":"Br J Dermatol"},{"key":"1421_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaad.2010.12.037","volume":"65","author":"LK Nieman","year":"2011","unstructured":"Nieman LK. Consequences of systemic absorption of topical glucocorticoids. J Am Acad Dermatol. 2011;65:250\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"1421_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40257-016-0230-4","volume":"18","author":"AK Gupta","year":"2017","unstructured":"Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol. 2017;18:67\u201375.","journal-title":"Am J Clin Dermatol"},{"key":"1421_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2010;62:191\u2013202.","journal-title":"J Am Acad Dermatol"},{"key":"1421_CR48","first-page":"e36","volume":"12","author":"A Samrao","year":"2013","unstructured":"Samrao A, Fu JM, Harris ST, Price VH. Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J Drugs Dermatol JDD. 2013;12:e36\u201340.","journal-title":"J Drugs Dermatol JDD"},{"key":"1421_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0190-9622(81)70017-3","volume":"4","author":"JP Callen","year":"1981","unstructured":"Callen JP. Intralesional corticosteroids. J Am Acad Dermatol. 1981;4:149\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1421_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0738-081X(86)90019-2","volume":"4","author":"RJ Coskey","year":"1986","unstructured":"Coskey RJ. Adverse effects of corticosteroids: I. Topical and intralesional. Clin Dermatol. 1986;4:155\u201360.","journal-title":"Clin Dermatol"},{"key":"1421_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2147\/CCID.S376096","volume":"16","author":"L Alhanshali","year":"2023","unstructured":"Alhanshali L, Buontempo MG, Lo Sicco KI, Shapiro J. Alopecia areata: burden of disease, approach to treatment, and current unmet needs. Clin Cosmet Investig Dermatol. 2023;16:803\u201320.","journal-title":"Clin Cosmet Investig Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01421-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01421-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:02:42Z","timestamp":1748689362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01421-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01421-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Arash Mostaghimi is an Editorial Board member of Dermatology and Therapy; Dr. Mostaghimi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Mostaghimi has received consulting fees from AbbVie, ACOM Health, Bioniz, Boehringer Ingelheim, Concert, Digital Diagnostics, Eli Lilly, Equillium, Hims & Hers Health, and Pfizer; equity from ACOM Health, Figure\u00a01, and Hims & Hers Health; licensing\/royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte.\u00a0Samantha Gregoire, Basil McIntosh, Katherine Sanchez, and Ursula Biba have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted research and did not involve performing research on any human participants or animals by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}